RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TRx Pharma announced today the availability of FOLMOR™ (folic acid 2.5mg, B6 25mg, B12 2mg and primorine 875mg), its novel, proprietary prescription product for the treatment of cardiovascular disease. Cardiovascular disease (CVD) is the leading cause of death among Americans. According to the American Heart Association, too much homocysteine is related to a higher risk of CVD. Oxidative stress, a harmful chemical process, is also implicated in the pathology of the disease. FOLMOR helps reduce elevated homocysteine levels and it thwarts the harmful effects of oxidative stress.
